Why two promising heart drugs flopped and what's next
On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And ...
10 Syys 30min
411: Capricor's data clash and a fugitive in the C-suite
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a ...
30 Heinä 36min
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a b...
23 Heinä 1h 4min
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the ma...
16 Heinä 35min
408: Whistleblower takes on health insurance and FDA commissioner candidates
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration ...
9 Heinä 43min
407: The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that...
25 Kesä 42min
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a clos...
18 Kesä 36min
405: An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experime...
11 Kesä 36min
